Introduction Glaucoma starting from the definition, unknown etiology for the primary cases, glaucoma suspect, ocular hypertension, early detection, diagnosis,

Slides:



Advertisements
Similar presentations
The target IOP is the mean IOP obtained with treatment that prevents further glaucomatous damage in the eye of the individual under consideration. The.
Advertisements

Paras Guide to Glaucoma
Selective Laser Trabeculoplasty: NSAIDs vs Steroids in Post-Operative Management Jennifer Calafati MD, Donna Williams-Lyn PhD, Iqbal Ike K. Ahmed MD, FRCSC.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute of Ophthalmology ARAVIND EYE CARE SYSTEM Aravind Eye Hospital & Postgraduate Institute.
Anterior Chamber Depth, Iridocorneal Angle Width, and Intraocular Pressure Changes After Phacoemulsification: Narrow vs Open Iridocorneal Angles Huang.
The Diabetic Retinopathy Clinical Research Network Repeated Intravitreous Ranibizumab Injections for DME and Risk of Sustained IOP Elevation or Need for.
4/19/2017 Managing Patients With Ocular Hypertension Results From The Ocular Hypertension Treatment Study (OHTS) The American Glaucoma Society Michael.
The Canadian Association of Optometrists
OPEN ANGLE GLAUCOMA Frank J. Weinstock, MD, FACS Professor of Ophthalmology- NEOUCOM Canton, Ohio USA.
Will my Glaucoma patient lose vision ?
Effects of Smoking on Corneal Thickness Candice Giordano, MD February 25, 2011.
RANDOMIZED CLINICAL TRIALS IN GLAUCOMA- WHAT DO THEY TELL US? Dr Jyoti Shetty B.W.Lions superspeciality eye hospital.
TARIQ ALASBALI WHICH PATIENTS ARE AT RISK FOR THE PROGRESSION?
QUANTITATING THE IMPACT OF CLINICAL AND BASIC SCIENCE RESEARCH POSTER #2469 M. O. GORDON, C. SARLI, E. K. DUBINSKY, E. LONG, C. LA RUE, M. A. KASS, AND.
Universita’ di Catania, Italia Clinica Oculistica Dir.: Prof. A. Reibaldi Purpose: To evaluate the efficacy and safety of Pneumotrabeculoplasty (PNT) in.
Does Greater Long-Term IOP Variability Increase Probability of Primary Open Angle Glaucoma in the Ocular Hypertension Treatment Study (OHTS)? M.O. Gordon,
Beginner’s Technique with SLT
Effect of Corneal Thickness on Selective Laser Trabeculoplasty to Decrease Intraocular Pressure as Primary or Secondary Treatment of Glaucoma ASCRS 2010.
Safety and efficacy of bromfenac ophthalmic solution 0.09% (Xibrom™) compared to prednisolone acetate 1% for treatment of ocular inflammation following.
Effect of Race on Selective Laser Trabeculoplasty  1st author has no financial interest in the subject matter of this poster.  2nd and 3rd co-authors.
Introduction  Selective Laser Trabeculoplasty (SLT) uses a Q-Switched frequency- doubled (532 nm), low energy Nd:YAG laser, which targets melanocytes.
Canadian Ophthalmological Society Evidence-based Clinical Practice Guidelines for the Management of Glaucoma in the Adult Eye.
Blindness or low vision effects more than 3 million Americans 40 years and older, and this number is projected to reach 5.5 million by In addition.
E-Poster Rio de Janeiro Corneal Tomography and Biomechanics Study Group The study of the correlations of the optic disc size with Cornal Geometry and Biomechanical.
The Effect of Bimatoprost 0.03% vs Travoprost 0.004% in Patients on Latanoprost 0.005% Requiring Additional IOP Lowering Jeffrey A. Kammer, 1 Barry Katzman,
Glaucoma Care Project Team Members: Geoffrey T. Emerick, M.D. Erin Herlihy, B.S. Marilyn Hauser, M.B.A. Dianna Greening, R.N. Walter M. Jay, M.D Opportunity.
Sponsored by the National Eye Institute,
Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study De Moraes CG, Demirel S, Gardiner SK, et.
The Ocular Hypertension Treatment Study Group (OHTS)
Effect of East Asian Race on Selective Laser Trabeculoplasty ASCRS 2011 Minerva Kim Johns Hopkins University Lawrence F. Jindra, MD Columbia University.
Effect of Refractive State on Selective Laser Trabeculoplasty ASCRS 2011 Kevin Lai Stony Brook University School of Medicine Elaine M. Miglino Floral Park.
Bromfenac Sodium Hydrate is Effective in Treating Intraoperative Discomfort during Selective Laser Trabeculoplasty ASCRS 2009 Marie T. Natale Floral Park.
Dr. T. Sarada M.S. Ophthalmology.  Congenital and developmental Glaucomas  Without associated anomalies - Primary congenital  With associated anomalies.
Dorzolamide A topical Carbonic anhydrase inhibitor. Ampholytic characteristics, hence good corneal penetration (depot effect achieved in cornea). Achieves.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Effect of Latanoprost, Brimonidine, and a Fixed.
Glaucoma Madhav Vempali Vempali Medical Ltd. Glaucoma The healthy eye Light rays enter the eye through the cornea, pupil and lens. These light rays are.
Glaucoma studies, IOP and treatment rationale W. H. Morgan RPH, LEI and PMH.
Mr. A. Waldock MD BMed Sci (Hons) BM BS FRCOphth Consultant Ophthalmic Surgeon Ophthalmology Training Programme Director, East of England Deanery.
The Royal Victorian Eye and Ear Hospital 24-hour eye pressure and glaucoma Dr Simon Skalicky FRANZCO, MPhil, MMed (Ophthal Sci), MBBS (Hons 1) Visiting.
Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Genetic Risk of Primary Open-angle Glaucoma: Population-Based.
Six-Year Longevity of Selective Laser Trabeculoplasty as Primary Therapy in Patients with Glaucoma ASCRS 2009 Lawrence F. Jindra, MD Columbia University.
Effect of Previous Argon Laser Trabeculoplasty on Selective Laser Trabeculoplasty ASCRS 2011 Lawrence F. Jindra, MD Columbia University Winthrop University.
Date of download: 6/3/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Cost-effectiveness of Medications Compared With Laser.
Glaucoma Lily T. Im, MD. What is glaucoma?   Glaucoma is a group of diseases that damage the eye’s optic nerve and can result in vision loss and blindness.
D.r Nishant Nawani, MS Dr. Surinder Singh Pandav, MD Dr. Amit Gupta, MD Dr. Sushmita Kaushik, MD Advanced Eye Centre PGIMER, Chandigarh The authors have.
(Relates to Chapter 22, “Nursing Management: Visual and Auditory Problems,” in the textbook) Copyright © 2011, 2007 by Mosby, Inc., an affiliate of Elsevier.
Understanding Glauco ma. Femi Babalola Rachel eye center Garki, Abuja.
Surgical Outcomes In Children With Primary Childhood Glaucoma
iStent with phacoemulsification, n=50
María Alejandra Carrasco, MD Mendoza. Argentina
PROTECTING CELLS IN THE EYE AT RISK OF DAMGE FROM GLAUCOMA
Tulsi Changulani 1,*, Jenny Bo 2, Mei-Ling Cheng 1, Andrew Tatham 1
Selective laser trabeculoplasty in Korean eyes with medically uncontrolled pseudoexfoliation glaucoma Su Chan Lee1, Jung Hyun Lee1,
Target IOP Update Mohamed Yasser Sayed Saif Beni Suef University
Safety of medication reduction for Primary Angle Closure (PAC) –
Glaucoma Suspect - Shields Textbook of Glaucoma, 6th edition - 녹내장 개정5판, 한국녹내장학회 부천성모병원 안과 Ap.홍승우/R3 이국.
Review of Glaucoma Suspect
Neuroretinal Rim Recovery In Narrow Angle Glaucoma After Intraocular Pressure Lowering With Topical Medications  – Case Report Božić M.1,2, Marković V.
A presentation to: Meeting name Date
Selective Laser Trabeculoplasty (SLT) as replacement therapy
Effect of Selective Laser Trabeculoplasty on
Risk stratification and calculators
Winthrop University Hospital
Clinical Cases in Glaucoma Treatment
Clinical study of open angle glaucoma surgery treatment trough deep slerectomy with T-Flux NV implant: three years follow-up Dr. Marco Rossi Dr Michele.
Winthrop University Hospital
The Effect of Corneal Thickness on Ocular Drug Penetration
ASCRS 2010 Joseph A. Donnelly Albert Einstein College of Medicine
Floral Park Ophthalmology Winthrop University Hospital
Presentation transcript:

Introduction Glaucoma starting from the definition, unknown etiology for the primary cases, glaucoma suspect, ocular hypertension, early detection, diagnosis, and details of management are all controversial. But the DDLS7 and this study for early detection and target IOP are milestones in our understanding of many of the controversies keeping in mind that multiplicity means satisaction of none. What is new? The risk factors for getting glaucoma include age, race, sex, heredity, family history, systemic (Diabetes, Obesity, Hypertension, Hypotension, arteriosclerosis and smoking) and socioeconomic factors as well as local factors (myopia, corneal thickness and scleral rigidity) all will channel into disc damage for the systemic factors and level of IOP for the local factors. So calculation of the combined probability of getting glaucoma for these 2 factors alone will include all the above mentioned variables. 8 For the calculation of the combined probability of getting glaucoma the study will analyze the probability of getting glaucoma in relation to IOP alone (X axis in table I) then the probability in relation to cup disc ratio (Y axis in table I). Also the combined probability for every X = IOP and every Y=C/D ratio Figure 1 demonstrates the probability of getting glaucoma (Y1)in relation to the IOP(X) and its derived equationY1=Y0+A1eX/T1 Y1= the probability of the incidence of POAG in the next 5 years when the IOP = x1 ( modified from Davanger M, Ringvold A, Bilka S. The probability of having glaucoma at different IOP levels. Acta Ophthalmol. 1991;69:565-8)9 Figure 2 : demonstrates the probability of getting glaucoma (Y2) in relation to the C/D ratio (X)Y2=Y0+A1eX/T1 Y2= the probability of the incidence of POAG in the next 5 years when the C/D ratio = x2 8 (formulated from the results of Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology Apr;105(4):733-9.)6 The combined probability will take in consideration the IOP (Y1) and the C/D (Y2) ratio as the resultant outcome as shown in table1. 8 Y1+Y2 2 Target IOP The target IOP is still another dilemma. different methods for estimation of the target IOP are well known. the most popular is a percent reduction of 40%, 30% and 20 % according to the maximum base line pressure not including the field changes or the disc damage in the calculations. Other methods which include these 2 factors are still not satisfactory. In our study. cases in whom treatment is necessary we have to achieve the target IOP. Our target IOP is to reduce the pressure to a probability of 0.10 or maximally 0.20 if it is possible taking in consideration that the IOP has to be corrected for any change in the corneal thickness or scleral rigidity. The target pressure in our study is related to the C/D ratio (corrected). table 2)Management Management again is still a dilemma. how? Medical treatment : The first drug to be used in early glaucoma or glaucoma suspect and even a definite case of glaucoma is still controversial. Again the second add is also a dilemma. The alternatives of the combined therapy are at a debate. The clinical trials and guide lines will stop all the controversies and the debate The guide lines in our study are as follows: –Normal: nothing to be done –Possible : observe –Probable: treat and observe –Highly probable: treatment vigorously & observe –Definite: full tolerable treatment, laser or surgery & observe Laser treatment : Argon laser trabeculoplasty (ALT) stood the test of time but other alternatives are in the way the success rate is still relatively low. we are far from perfection. i.e. still there is a dilemma. Surgical treatment: Our golden standard is the trabeculectomy but the non0penetrating glaucoma surgery change the position of the trabeculectomy until the moment there is a dilemma. ConclusionConclusion : Glaucoma starting from the definition, unknown etiology for the primary cases, glaucoma suspect, ocular hypertension, early detection, diagnosis, and details of management are all controversial. But the DDLS7 and this study for early detection and target IOP are milestones in our understanding of many of the controversies ReferencesReferences : 1. Weinreb RN, Kitazawa Y, Krieglstein GK. Glaucoma in the 21st century. Published by Harcourt Health Communications, a division of Mosby International Ltd, Mukesh BN, McCarty CA, Rait JL, Taylor HR. Five-year incidence of open-angle glaucoma: the visual impairment project. Ophthalmology Jun;109(6): Weih LM, Nanjan M, McCarty CA, Taylor HR. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology Nov;108(11): Rochtchina E, Mitchell P. Projected number of Australians with glaucoma in 2000 and Clin Experiment Ophthalmol Jun;28(3): Wensor MD, McCarty CA, Stanislavsky YL, Livingston PM, Taylor HR. The prevalence of glaucoma in the Melbourne Visual Impairment Project. Ophthalmology Apr;105(4): Speath GL, Henderer J, Steinmann W. The disc damage likelihood scale (DDLS), Its use in the diagnosis and management of glaucoma. Highlights of ophthalmology. Vol 31 number 4 ; P 4-19; Saif SSEH, Saif MYS, Saif ATS. Early Detection of Glaucoma, A New Scoring System; Bull. Ophthalmol. Soc. Egypt,2005;vol 98,number 3, Davanger M, Ringvold A, Bilka S. The probability of having glaucoma at different IOP levels. Acta Ophthalmol. 1991;69: Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open ‑ angle glaucoma. Arch Ophthalmol. 2002; 120:714 ‑ Kass MA, Heuer UK, Higginbotham I;J, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open ‑ angle glaucoma. Arch Ophthalmol. 2002;120:701 ‑ Preferred Practice Patterns Committee, Glaucoma Panel. Primary Open ‑ Angle Glaucoma Suspect. San Francisco: American Academy of Ophthalmology; Alvarado J, Murphy C, Juster R. Trabecular meshwork cellularity in primary open angle glaucoma and nonglaucomatous normals. Ophthalmology 1984;91: Carlo E Traverso. Identifying the target intraocular pressure and adjusting treatment In Robert N Weinreb, Yoshiaki Kitazawa, Günther K Krieglstein, ; Glaucoma in the 21st Century ; Mosby International Ltd 2000 published by Harcourt Health communication 14.Collaborative Normal ‑ Tension Glaucoma Study Group. Comparison of glaucoma progression between untreated patients with normal tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487 ‑ Collaborative Normal ‑ Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal ‑ tension glaucoma. Am j Ophthalmol 1998;126:498 ‑ Traverso CE, Semino E, Morescalchi S, et al. Is the visual field of patients with advanced POAG protected by lowering the IOP? In: Mills RP, Wall M, eds. Perimetry update 1994/1995. Amsterdam: Kugler; 1995:309 ‑ 312. Is it still a dilemma in the 21st century? Prof Dr Sayed S. E. H. Saif, MD Dr M. Yasser S Saif, MD ; Dr Ahmed T.S. Saif, MD*** Professor of Ophthalmology, Cairo University Lecturer of Ophthalmology, Beni Sweif University Lecturer of Ophthalmology, Fayoum University Early diagnosis Accordingly people are classified after calculation of the probability of getting glaucoma into the following: Normal up to 0.10 on the probability scale with normal IOP up to 21 mmHg and C/D ratio up to 0.5: (Nothing to be done) Ocular hypertension in whom the rise of IOP above 21 mmHg is the only sign with normal C/D ratio and their management will follow the general scheme of possible, probable, or definite as will be demonstrated. Possible up to 0.20 on the probability scale with rise of IOP more than 21 mmHg and increase of C/D ratio but the combined probability will not exceed 0.20.(Observation) Probable up to 0.30 on the probability scale (these has to be treated and observed) a monotherapy may be sufficient to achieve the target IOP Highly probable up to 0.40 on the probability scale (treatment vigorously and observe) a bi-therapy may be needed to achieve the target IOP Definite more than 0.40 on the probability scale (full tolerable treatment, laser or surgery and observe to achieve the target IOP) Subject and methods: The following are examples to demonstrate how to manage these problematical cases using table 1 for early detection and diagnosis and table 2 for estimation of the target IOP. A : Glaucoma suspect B: Established Glaucoma The diagnosis is easy but the target IOP is problematical Web Page: Tel: ,